Lynn Schuchter, MD, Chief, Division of Hematology/Oncology at Penn Medicine presents on the benefits of personalized diagnostics and genomic testing for patients with melanoma, with a focus on BRAF mutant melanoma and BRAF/MEK inhibitor therapy, and the ways oncologists are managing acquired resistance to therapy.
Related Links
Published
October 14, 2013
Created by
BROADCASTMED